Our Curious Amalgam

Toggle navigation
  • About
  • Hosts
  • Gallery
  • Episodes
  • ABA
  • Search

#172 Biologically Similar but Competitively Not So? Economic Considerations of IP Litigation Settlements Involving Biosimilars

https://ourcuriousamalgam.com/episode-player/2256/172-biosimilars-ip-litigation-settlements.mp3?stats-code=ocaPodcastSite

Under the U.S. Supreme Court case FTC v. Actavis (2013), antitrust analysis of “reverse settlements” of IP litigations between makers of branded small molecule drugs and generics requires an analysis under the rule of reason. Are there distinct challenges presented by settlements between branded biologics and biosimilars? Sean Sheridan and Archan Ruparel, principals at Charles River Associates, speak with Anora Wang and Christina Ma on the complexities of negotiating patent settlements involving biosimilars. Listen to this episode to learn about pharmaceutical entry, price erosion, and more.

Sean Sheridan, Principal, Charles River Associates

Archan Ruparel, Principal, Charles River Associates

Sean Sheridan, Principal, Charles River Associates
Archan Ruparel, Principal, Charles River Associates

Related Links:

Sean Sheridan and Archan Ruparel, FDA Biosimilar Approval Foreshadows IP Litigation Issues (September 15, 2021)

Hosted by:

Anora Wang, Arnold & Porter and Christina Ma, Wachtell, Lipton, Rosen & Katz


Posted On June 13, 2022

Posted By Our Curious Amalgam

Posted In Antitrust Economics PRACTICES

Tagged analysis antitrust biologics biosimilars competition economics generics intellectual property law litigation market payment pharmaceutical settlement

Share


Prev

#171 Can the Federal Trade Commission Use Rulemaking To Change Antitrust Laws? A Closer Look at the Administrative Law Challenges With Prof. Richard Pierce

Next

#173 Who Is Alejandra Palacios? Meet the Former Chair of the Mexican Federal Economic Competition Commission (COFECE)

Scroll to the top

Don't miss new episodes every Monday. Subscribe now!

Our Curious Amalgam explores topics in antitrust, competition, consumer protection, data protection, and privacy law around the world with leading experts in those areas. It is an amalgam because it is a group of diverse topics all in one place. It is curious because it gets the experts and asks them in-depth questions.

© 2019-2023 American Bar Association. All Rights Reserved.

NEWS AND EVENTS
What's Going on at the Antitrust Law Section

CONTACT US
podcast@ourcuriousamalgam.com

Find us on social!

Facebook Twitter Instagram LinkedIn RSS Feed

Subscribe
Subscribe on iTunes
Listen on Spotify
Listen on Google Podcasts
Listen to Stitcher
Amazon music
The opinions expressed by the participants in the podcasts are their own and do not necessarily represent those of their employers or other affiliated organizations.